AVN-322

AVN-322 is a 5-hydroxytryptamine subtype 6 receptor antagonist manufactured by Avineuro Pharmaceuticals Inc. that could potentially be used to combat Alzheimer's disease and schizophrenia.[2][3] AVN-322 also reverses the negative effects of scopolamine and MK-80.[3]

AVN-322
Names
IUPAC name
5-(benzenesulfonyl)-N,11-dimethyl-2,3,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7-tetraen-4-amine;hydrochloride
Other names
List
  • 1194574-68-9
  • SB17475
  • 5-(Benzenesulfonyl)-N,11-dimethyl-2,3,7,11-tetraazatricyclo(7.4.0.0(2,6))trideca-1(9),3,5,7-tetraen-4-amine hydrochloride
  • starbld0039763
[1]
Properties
C17H20ClN5O2S
Molar mass 393.891 g/mol
Identifiers
ChemSpider
UNII
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

The compound is a sister drug to AVN-101 and AVN-211, two similar compounds under trial for treating Alzheimer's.[3] Phase I trials for the drug were initiated in 2009 by Avineuro, and completed in the spring of 2010.[4][5] The trials showed that AVN-322 was tolerated in a range of doses without any adverse effects, and Avineuro released plans to commence Phase II trials later the same year.[5] The plan for further trials was discontinued in 2013.[6]

References
  1. National Center for Biotechnology Information. "Compound Summary for CID 135905417, B7DM6S48B2" PubChem. Accessed 12 March 2023.
  2. "AVN-322 | CAS#1194574-68-9 | CAS#1194574-33-8 | 5-HT6 Antagonist | MedKoo". www.medkoo.com. Retrieved 2023-03-12.
  3. Andrews, Megan; Tousi, Babak; Sabbagh, Marwan N. (2018-06-01). "5HT6 Antagonists in the Treatment of Alzheimer's Dementia: Current Progress". Neurology and Therapy. 7 (1): 51–58. doi:10.1007/s40120-018-0095-y. ISSN 2193-6536. PMC 5990506. PMID 29728891. S2CID 19186491.
  4. "Avineuro Announces Beginning Of Phase I Clinical Studies Of AVN-322, Potent Small Molecule For Treatment Of Alzheimer's Disease". BioSpace. Archived from the original on 12 Mar 2023. Retrieved 2023-03-12.
  5. "Avineuro Reports Positive Phase I Clinical Trial Results On AVN-322, Potent Small Molecule For Treatment Of Alzheimer's Disease". BioSpace. Archived from the original on 12 Mar 2023. Retrieved 2023-03-12.
  6. "Phase II trial of AVN 322 in patients with Alzheimer's disease. - AdisInsight". adisinsight.springer.com. Retrieved 2023-03-12.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.